García-López Celia, Rodríguez-Calvo-de-Mora Marina, Borroni Davide, Sánchez-González José-María, Romano Vito, Rocha-de-Lossada Carlos
Department of Ophthalmology, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Department of Ophthalmology, Hospital Regional Universitario de Málaga, Málaga, Spain; Department of Ophthalmology (Qvision), Vithas Almería, Almería, Spain; Department of Ophthalmology, VITHAS Málaga, Málaga, Spain.
Surv Ophthalmol. 2023 Sep-Oct;68(5):929-939. doi: 10.1016/j.survophthal.2023.06.007. Epub 2023 Jun 21.
During infectious keratitis, the production of collagenolytic and inflammatory substances, along with increased corneal matrix metalloproteinase (MMP) activity, induces the degradation of corneal collagen and may cause postkeratitis complications, such as opacity, thinning, and corneal perforation. MMPs, especially MMP-2 and MMP-9, are overexpressed in infectious keratitis and sustained over time by inflammatory and nonmicrobial mechanisms. The high MMP levels are correlated with excessive corneal destruction in bacterial, herpetic, fungal, and acanthamoeba infections. Nonspecific treatments, such as tetracyclines, particularly doxycycline, or corticosteroids, are used as adjuvants to antimicrobials to alleviate the disproportionate degradation and inflammation of the corneal layers caused by corneal MMPs and decrease the recruitment and infiltration of inflammatory cells. Treatments showing inhibition of specific MMPs (Galardin, ZHAWOC7726), interfering with pro-MMP activation (EDTA, ascorbic acid), or showing anticytokine effect (epigallocatechin-2-gallate, TRAM-34) have been reported. Other treatments show a direct action over corneal collagen structure such as corneal cross-linking or have been associated with reduction of MMP levels such as amniotic membrane grafting. Although the use of these drugs has been shown in studies to be effective in controlling inflammation, especially in experimental ones, robust studies are still needed based on randomized and randomized clinical trials to demonstrate their potential effect as adjuvants in the management of infectious keratitis.
在感染性角膜炎期间,胶原分解和炎性物质的产生,以及角膜基质金属蛋白酶(MMP)活性增加,会诱导角膜胶原蛋白降解,并可能导致角膜炎后并发症,如角膜混浊、变薄和角膜穿孔。MMP,尤其是MMP-2和MMP-9,在感染性角膜炎中过度表达,并通过炎症和非微生物机制随时间持续存在。高MMP水平与细菌、疱疹、真菌和棘阿米巴感染中角膜的过度破坏相关。非特异性治疗,如四环素,特别是强力霉素,或皮质类固醇,用作抗菌药物的佐剂,以减轻由角膜MMP引起的角膜层不成比例的降解和炎症,并减少炎性细胞的募集和浸润。已有报道显示某些治疗可抑制特定MMP(加拉迪恩、ZHAWOC7726)、干扰前MMP激活(乙二胺四乙酸、抗坏血酸)或具有抗细胞因子作用(表没食子儿茶素-2-没食子酸酯、TRAM-34)。其他治疗方法对角膜胶原结构有直接作用,如角膜交联,或与MMP水平降低有关,如羊膜移植。尽管在研究中已表明使用这些药物在控制炎症方面有效,尤其是在实验研究中,但仍需要基于随机和随机临床试验的有力研究来证明它们作为感染性角膜炎治疗佐剂的潜在效果。